[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 65, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 51, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1158083, "exercisedValue": 0, "unexercisedValue": 1257688}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 46, "title": "Senior VP, CFO, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 626233, "exercisedValue": 0, "unexercisedValue": 47925}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 45, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 526431, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Thompson M.A., M.S., Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Chairman of Scientific Advisory Board & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.05, "open": 3.09, "dayLow": 2.86, "dayHigh": 3.09, "regularMarketPreviousClose": 3.05, "regularMarketOpen": 3.09, "regularMarketDayLow": 2.86, "regularMarketDayHigh": 3.09, "beta": 1.54, "forwardPE": -1.862839, "volume": 415909, "regularMarketVolume": 415909, "averageVolume": 490520, "averageVolume10days": 531140, "averageDailyVolume10Day": 531140, "bid": 2.89, "ask": 2.95, "bidSize": 200, "askSize": 100, "marketCap": 187581392, "fiftyTwoWeekLow": 2.385, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 3.5185, "twoHundredDayAverage": 4.721675, "currency": "USD", "enterpriseValue": 107262192, "floatShares": 36521837, "sharesOutstanding": 64240200, "sharesShort": 3407026, "sharesShortPriorMonth": 3229758, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.053000003, "heldPercentInsiders": 0.00505, "heldPercentInstitutions": 0.98528, "shortRatio": 7.59, "shortPercentOfFloat": 0.0573, "impliedSharesOutstanding": 64240200, "bookValue": 1.29, "priceToBook": 2.263566, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -96494000, "trailingEps": -1.55, "forwardEps": -1.62, "enterpriseToEbitda": -1.085, "52WeekChange": -0.32563508, "SandP52WeekChange": 0.25891924, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.92, "targetHighPrice": 43.0, "targetLowPrice": 12.0, "targetMeanPrice": 19.55556, "targetMedianPrice": 15.0, "recommendationKey": "none", "numberOfAnalystOpinions": 9, "totalCash": 131608000, "totalCashPerShare": 2.049, "ebitda": -98893000, "totalDebt": 46792000, "quickRatio": 7.174, "currentRatio": 7.683, "debtToEquity": 56.52, "returnOnAssets": -0.35691002, "returnOnEquity": -0.79419, "freeCashflow": -55929500, "operatingCashflow": -91206000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]